Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
about
Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaA Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemiaCurrent concepts in diagnosis and treatment of chronic lymphocytic leukemiaNew developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumabProteomics-based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunitiesClinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentTherapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaMatrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxideObinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.Autoimmune thrombocytopenia: a complication of fludarabine therapy in the treatment of Waldenstrom's macroglobulinemiaJAK2 V617F detected in two B-cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome-negative myeloproliferative neoplasms: A report of two cases.Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.Targeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells.Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2High Viral Loads of Epstein-Barr Virus DNA in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Associated with Unfavorable Prognosis.The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemiaCharacteristics of chronic lymphocytic leukemia in SenegalPrimary care management of early stage chronic lymphocytic leukaemia is safe and effectiveAssociation between the cytogenetic profile of tumor cells and response to preoperative radiochemotherapy in locally advanced rectal cancer.Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US iIbrutinib: a paradigm shift in management of CLL.Practical approach to management of chronic lymphocytic leukemiaAssessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia.t(14;18)(q32;q21) in chronic lymphocytic leukemia patients: Report of two cases and a literature review.Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario.Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemiaTP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498.A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia.
P2860
Q26749010-5BF63C23-E241-42F8-8962-69F91475067FQ26766388-0B602A46-E672-46BF-B126-CE9386CC8791Q26770471-C38E3668-43B4-4F8B-AC34-3177272A699EQ26801292-3129024B-6681-4822-9EDF-A07A9B0F585FQ26861489-0D215DFC-A3DD-4957-9034-FB0F7408ADD2Q27853333-C267C67A-54C3-435B-9AEA-F474A8B31A28Q28082086-13EEB79B-9959-484D-AE7E-9AB701195E78Q28087378-0074A722-4F13-4AA5-A12F-889D0449BC09Q28539921-CB96DD0A-F976-49DB-B540-76D45ECC3A11Q33416524-23568056-8B4C-47A0-89B4-A6414A4A5E3EQ33417548-7CAAB25F-BD6D-462B-A988-5243B83574D6Q33420255-54BD4831-068B-4E54-AE3D-8D5C44D89E16Q33843882-C82C2669-59B1-44D8-A003-A4BB847439F6Q33913537-367BDDE8-3C3D-4603-BBC7-7A39720F95CEQ34052075-4C05E3E4-5627-428E-A311-DF28F91A214AQ34507114-6BAA302D-A4A1-4A21-9FDE-A8C375A48746Q34704085-6DFC9D23-4F05-4BF3-953C-93F991F8A4C1Q35020381-172DA23B-1181-476E-8B64-28CA7C924A00Q35110582-89A1082A-08C9-4CEB-BA33-BB280C1904E5Q35128888-601BB252-FE5C-4C9C-A737-0D0AFB73BE74Q35550068-53FB7806-4D82-45DD-B024-05FE429875C6Q35582556-2EC1FF0E-7AC1-4E80-BA5C-40AB4922860BQ35646876-CC7B67BD-BDD0-422E-B325-1C4FA23A29DAQ35722786-06411681-226B-46EC-966E-0070459FF4A6Q35804493-D83208DF-B370-4077-A8B4-39EA364B34C5Q35941236-99C158F3-32AD-431E-9F14-BB108B67ED87Q35997917-62915BA0-3042-4045-A3B4-D241587AE657Q36103295-B7FDCAE8-A30F-4223-8A11-5BF47E82084FQ36193815-0369EF48-0545-46E5-B23F-2C170F80A280Q36397924-A3DB196C-EE8E-44E0-9C42-881645E65F69Q36739295-A95C9D4C-CA35-48F2-9F41-354DA77CB58EQ36845277-0A19E84A-03EB-4B5F-BB16-531611A59BBCQ37362785-140593C4-A54C-40BA-8F12-1CFE80E9C28AQ37582234-1C3A7A37-D341-4A71-8ED9-384A88C673AEQ37672029-3816C3F0-0CBA-46A7-A609-7E16B7D4C279Q37699259-AD29AB86-45C8-42C5-829B-BFCFF707B803Q38177771-02413001-66EA-4BFE-B3AF-A3131B5A0FD2Q38209572-2547A76C-5EFF-44F7-A5EA-30D20CC2035EQ38231432-7B039593-62E1-441A-91FB-906AD2E9544BQ38237264-19A04AEF-EDF6-43F0-8295-F1FAA180A7E9
P2860
Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Chronic lymphocytic leukemia: ...... stratification and treatment.
@en
type
label
Chronic lymphocytic leukemia: ...... stratification and treatment.
@en
prefLabel
Chronic lymphocytic leukemia: ...... stratification and treatment.
@en
P2860
P356
P1476
Chronic lymphocytic leukemia: ...... stratification and treatment.
@en
P2860
P304
P356
10.1002/AJH.23491
P577
2013-09-01T00:00:00Z